Article (Scientific journals)
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to "A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands" by Dr. Germo Gericke.
Herrmann, Ken; Kratochwil, Clemens; Fendler, Wolfgang P et al.
2021In European Journal of Nuclear Medicine and Molecular Imaging, 48 (9), p. 2668 - 2669
Peer Reviewed verified by ORBi
 

Files


Full Text
259_2021_Article_5409.pdf
Publisher postprint (125.24 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Dipeptides; Heterocyclic Compounds, 1-Ring; Ligands; PSMA-617; Radioisotopes; Prostate-Specific Antigen; Humans; Radiology, Nuclear Medicine and Imaging
Disciplines :
Radiology, nuclear medicine & imaging
Author, co-author :
Herrmann, Ken;  Department of Nuclear Medicine, Universitätsklinikum Essen, Essen, Germany. Ken.Herrmann@uk-essen.de
Kratochwil, Clemens;  German Cancer Research Center and Department of Nuclear Medicine, Universitätsklinikum Heidelberg, Heidelberg, Germany
Fendler, Wolfgang P;  Department of Nuclear Medicine, Universitätsklinikum Essen, Essen, Germany
Eiber, Matthias;  Klinikum rechts der Isar, Technische Universität München, Munich, Germany
Hustinx, Roland  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service médical de médecine nucléaire et imagerie onco
Language :
English
Title :
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to "A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands" by Dr. Germo Gericke.
Publication date :
August 2021
Journal title :
European Journal of Nuclear Medicine and Molecular Imaging
ISSN :
1619-7070
eISSN :
1619-7089
Publisher :
Springer Science and Business Media Deutschland GmbH, Germany
Volume :
48
Issue :
9
Pages :
2668 - 2669
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
Universitätsklinikum Essen [DE]
Funding text :
The authors are active Nuclear Medicine practitioners and true believers in theranostics. Ken Herrmann reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics and personal fees from Pharma15, outside the submitted work. Clemens Kratochwil is a co-inventor of the PSMA-617 patent. Wolfgang P. Fendler was a consultant for BTG, and he received fees from RadioMedix, Bayer and Parexel outside of the submitted work. Matthias Eiber reports prior consulting activities for Blue Earth Diagnostics, Progenics Pharmaceuticals and Point Biopharma and a patent application for rhPSMA outside of the submitted work. No further conflicts of interest in regard to this letter to the editor.
Available on ORBi :
since 22 August 2023

Statistics


Number of views
100 (2 by ULiège)
Number of downloads
69 (1 by ULiège)

Scopus citations®
 
2
Scopus citations®
without self-citations
2
OpenCitations
 
1

Bibliography


Similar publications



Contact ORBi